US EditionHistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
- HistoIndex closed a S$9 million investment round led by OCBC to support its expansion in the US and AI pathology development.
- The investment is driven by a rising need for regular clinical evaluations of Metabolic Dysfunction-Associated Steatohepatitis, with an emphasis on liver biopsy analysis.
- HistoIndex, founded in 2010, pioneers biophotonic Second Harmonic Generation technology and AI digital pathology for managing fibrotic diseases.
- CEO Dr. Gideon Ho stated that the funding supports the company’s plans to expand strategically in the US and helps advance innovative diagnostic solutions.
- This investment is expected to accelerate adoption of HistoIndex’s AI-based pathology tools, potentially transforming MASH diagnosis and personalized treatment worldwide.
Insights by Ground AI
Does this summary seem wrong?
67 Articles
67 Articles
All
Left
6
Center
25
Right
3
HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion
SINGAPORE, May 1, 2025 /PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9…
Coverage Details
Total News Sources67
Leaning Left6Leaning Right3Center25Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 18%
C 74%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
